<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of giant cell arteritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of giant cell arteritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of giant cell arteritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria C Cid, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Warrington, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1804187647"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Giant cell arteritis (GCA) is a chronic inflammatory disease involving large- and medium-sized arteries and affecting individuals older than 50 years [<a href="#rid1">1</a>]. Involvement of the cranial branches of the carotid arteries is very common and, due to its easy access, biopsy of the superficial temporal artery is frequently performed to obtain histopathologic confirmation of GCA.</p><p>Histopathology and immunopathology studies reveal inflammation of the artery wall with predominance of CD4+ T lymphocytes and macrophages, which frequently undergo granulomatous organization with formation of giant cells [<a href="#rid2">2</a>]. There is a remarkable loss of vascular smooth muscle cells (VSMC) and elastic fibers that may eventually facilitate aneurysm formation. Inflammation-induced vascular remodeling leads to intimal hyperplasia and lumen occlusion, the source of the ischemic complications of the disease [<a href="#rid1">1,2</a>].</p><p>The pathogenesis of GCA is incompletely understood. The current pathogenic model has been largely built on immunopathology and molecular studies performed with temporal artery biopsies. Functional models where the participation of specific pathways can be mechanistically investigated are limited. The role of particular cells, molecules, or pathways has been investigated in temporal artery biopsy xenografts into severe combined immunodeficiency (SCID) mice or in ex vivo cultured arteries [<a href="#rid3">3,4</a>]. Clinical trials with targeted therapies are providing proof of concept about the relevance of specific pathways in the pathogenesis of vascular inflammation [<a href="#rid5">5</a>].</p><p>This topic will review the pathogenesis of GCA. The clinical manifestations, diagnosis, and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a> and  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H495771663"><span class="h1">PREDISPOSING FACTORS</span><span class="headingEndMark"> — </span>Epidemiologic studies demonstrate predominance in older adults, females, and individuals of Northern European ancestry. Occasional family clustering has been reported. These data strongly suggest that senescence, sex, and genetic background all contribute to the pathogenesis of giant cell arteritis (GCA) [<a href="#rid1">1</a>]. The role of aging and sex remains elusive.</p><p>Along with candidate gene studies performed over the years, an international large-scale genotyping effort has confirmed a strong association between GCA and genetic variants in the major histocompatability complex (MHC) region, particularly human leukocyte antigen (HLA)-DRB1*04:04, HLA-DQA1*03:01, and HLA-DQB1*03:02. The derived risk amino acids are located in the antigen-binding pocket of the HLA molecule. These findings support the role of adaptive immunity and the concept that GCA may be an antigen-driven disease [<a href="#rid6">6-8</a>].</p><p>A genome-wide association study indicates that, in addition to MHC polymorphisms, variants in genes related to angiogenesis and vascular biology also predispose to GCA [<a href="#rid7">7</a>]. Additional variants in genes involved in T helper (Th) 1, Th17, and regulatory T-cell function associated with increased GCA risk have also been identified at a subgenome-wide significance level [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H366497907"><span class="h1">INITIAL EVENTS</span><span class="headingEndMark"> — </span>The nature of the triggering agent(s) has not been identified with certainty  (<a class="graphic graphic_figure graphicRef138875" href="/z/d/graphic/138875.html" rel="external">figure 1</a>). Periodic increases in incidence observed in some epidemiologic studies suggest a role for environmental factors [<a href="#rid9">9</a>]. Various microbe and viral sequences have been detected in temporal artery lesions, but no convincing causal relationship has been demonstrated [<a href="#rid10">10-14</a>].</p><p class="headingAnchor" id="H3855052368"><span class="h2">Dendritic cell and T lymphocyte activation</span><span class="headingEndMark"> — </span>Dendritic cells, present in the adventitia of normal arteries, can be activated in giant cell arteritis (GCA) through pathogen- or damage-sensing receptors, such as toll-like receptors, and produce chemokines able to attract and retain dendritic cells as well as lymphocytes and macrophages. These data underline the participation of innate immunity in initial pathogenic events [<a href="#rid15">15</a>]. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is emerging as a relevant cytokine in dendritic cell and macrophage activation in GCA, influencing several steps in pathogenesis [<a href="#rid16">16</a>].</p><p>Once activated, dendritic cells are enabled to process and present antigens and strongly express activation markers (ie, CD83), major histocompatibility complex (MHC) class II, and costimulatory molecules (ie, CD86) required for antigen presentation and T-cell activation [<a href="#rid15">15</a>]. The involvement of antigen-specific adaptive immune responses is supported by the detection of oligoclonal expansion of T cells in GCA lesions [<a href="#rid17">17</a>]. Genes related to T-cell activation (ie, transcription factor nuclear factor of activated T cells [NFAT] and NFAT-regulated genes) are hypomethylated in GCA-involved arteries, supporting a central role for T lymphocytes in disease pathogenesis [<a href="#rid18">18</a>]. Immune checkpoints avoiding excessive T-cell activation may be deficient in GCA [<a href="#rid19">19</a>]. Their functional relevance is supported by the development of GCA in cancer patients treated with immune checkpoint inhibitors [<a href="#rid20">20,21</a>] and by the efficacy of <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> (a soluble fusion protein comprising cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] and the Fc portion of immunoglobulin [Ig] G1 [CTLA-Ig]) in GCA, reported in a phase II trial [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Unproven or ineffective agents'</a>.)</p><p class="headingAnchor" id="H3304410749"><span class="h2">T lymphocyte functional differentiation</span><span class="headingEndMark"> — </span>After activation, T lymphocytes differentiate into T helper (Th) 1 and Th17 functional subsets as supported by the expression of the key effector cytokines interferon (IFN) gamma and interleukin (IL) 17, respectively, in GCA lesions [<a href="#rid23">23-27</a>]. Cytokines produced by dendritic cells drive this process. On the one hand, IL-12 and IL-18 produced by dendritic cells stimulate Th1 differentiation [<a href="#rid15">15,25</a>]. On the other hand, IL-1-beta, IL-6, and IL-21, profusely expressed in GCA [<a href="#rid23">23,24,27,28</a>], promote Th17 differentiation, which is maintained by IL-23. IL-12 and IL-23 share a common subunit IL-12/23p40 expressed in GCA at low levels [<a href="#rid29">29,30</a>]. By contrast, the IL-23p19 subunit is strongly expressed and may have an independent proinflammatory function in GCA [<a href="#rid30">30,31</a>]. Additional cytokines suggesting wider diversity of T-cell subsets (ie, IL-9, IL-22) can be detected in GCA lesions, but their role has not been characterized [<a href="#rid32">32,33</a>].</p><p>Regulatory T cells limiting immune activation are also present in vascular inflammatory lesions from patients with GCA [<a href="#rid25">25</a>]. However, in a strongly inflammatory microenvironment and, particularly, under the influence of IL-6, regulatory T cells may not be suppressive and may produce IL-17A [<a href="#rid25">25</a>]. Restoring the suppressive function of regulatory T cells may partially underlie the therapeutic effect of blocking IL-6 receptor with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> in GCA [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Tocilizumab'</a>.)</p><p class="headingAnchor" id="H474426253"><span class="h2">Potential role of B lymphocytes</span><span class="headingEndMark"> — </span>B lymphocytes cooperate in T-cell activation. While B cells are reduced in peripheral blood during active disease, they are present in GCA lesions, where they occasionally form tertiary lymphoid organs [<a href="#rid2">2,36,37</a>], particularly in aortic tissue [<a href="#rid38">38</a>]. However, the functional significance of this finding is not fully understood.</p><p class="headingAnchor" id="H670459555"><span class="h1">SUBSEQUENT EVENTS</span></p><p class="headingAnchor" id="H2893757693"><span class="h2">Amplification cascades</span><span class="headingEndMark"> — </span>Following T-cell activation and differentiation, amplification cascades are crucial to the development of transmural inflammation, and macrophages are major players in this process. Interferon (IFN) gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF) are markedly expressed in giant cell arteritis (GCA)-involved arteries and have a crucial role in macrophage activation and granuloma formation [<a href="#rid24">24,39</a>]. Interleukin (IL) 17A, expressed in GCA [<a href="#rid25">25</a>], is also a potent proinflammatory cytokine with pleiotropic effects on a variety of cells including macrophages, endothelial cells, vascular smooth muscle cells (VSMC), and fibroblasts. The majority of infiltrating macrophages are nonclassical (CD16+), with strong proinflammatory functions [<a href="#rid40">40</a>]. Proinflammatory macrophages produce a variety of cytokines with potent systemic and/or local effects that probably have important effects on disease manifestations and outcome. Expression of IL-1-beta, tumor necrosis factor (TNF)-alpha, IL-33, and IL-6 correlates with the intensity of the acute phase response typical of GCA [<a href="#rid24">24,28,41</a>]. These and other cytokines induce production of chemokines and expression of endothelial adhesion molecules, which are seminal in recruiting additional lymphocytes and monocytes, thus promoting vascular inflammation [<a href="#rid39">39,42</a>]. Under the influx of cytokines, VSMC also acquire a proinflammatory phenotype and actively facilitate progression of inflammatory infiltrates through the muscular layer [<a href="#rid39">39</a>].</p><p>Some of these cytokines have been considered as therapeutic targets, based on their known biologic functions and their association with disease activity. While blockade of TNF-alpha with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> was not clinically beneficial [<a href="#rid43">43,44</a>], blocking the IL-6 receptor with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> has been demonstrated to reduce relapses and reduce the dose of glucocorticoids required for disease control [<a href="#rid45">45</a>]. A phase II trial has demonstrated that blocking GM-CSF receptor-alpha with mavrilimumab prolongs glucocorticoid-induced remission and reduces relapse rate [<a href="#rid46">46</a>]. These results support an important role for IL-6 and for GM-CSF receptor signaling in sustaining inflammatory activity. Since a complex network of additional cytokines may be involved, blocking converging downstream signaling molecules, such as Janus kinases (JAK) may be an effective treatment approach, as suggested by an experimental model and small trial [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Tocilizumab'</a> and  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Unproven or ineffective agents'</a>.)</p><p>Angiogenic factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), and platelet-derived growth factors (PDGFs), mainly produced by macrophages, induce neovascularization and amplify vascular inflammation by providing new entries through which additional leukocytes will invade the vessel wall and supply the metabolic demands of the inflammatory process [<a href="#rid42">42,49</a>]. VEGF induces jagged 1 expression by endothelial cells from vasa vasorum and may trigger notch-dependent T lymphocyte differentiation [<a href="#rid50">50</a>]. Interestingly, in the context of vascular inflammation, angiogenesis may have a compensatory role preventing ischemia, and a strong angiogenic response is associated with reduced neuro-ophthalmic ischemic complications [<a href="#rid49">49,51</a>].</p><p class="headingAnchor" id="H4282585204"><span class="h2">Vascular injury</span><span class="headingEndMark"> — </span>The medial layer of inflamed arteries is invaded by inflammatory cells, resulting in a substantial loss of VSMC. The mechanisms for VSMC damage have not been investigated in depth. Cytotoxic CD8+ lymphocytes are present in the infiltrates and may induce VSMC apoptosis [<a href="#rid52">52</a>]. Macrophages produce reactive oxygen species leading to oxidative damage and may also contribute to vessel wall injury [<a href="#rid53">53</a>].</p><p>Expression of matrix metalloproteases MMP9 and MMP2, which have elastinolytic activity, is increased in GCA lesions, whereas their natural inhibitors TIMP1 and TIMP2 are reduced. This imbalance results in increased proteolytic activity in GCA infiltrates, leading to the disruption of the internal elastic lamina, typically observed in affected arteries [<a href="#rid54">54</a>]. Extensive disruption of the elastic fibers, as observed in the aorta, may favor delayed complications, such as aortic aneurysm, which is an increasingly recognized complication of the disease [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1907026250"><span class="h2">Vascular remodeling and occlusion</span><span class="headingEndMark"> — </span>Activated macrophages and injured VSMC produce growth factors and other products able to promote myofibroblast differentiation of VSMC. Myofibroblasts migrate towards the intimal layer and produce extracellular matrix proteins, resulting in intimal hyperplasia and arterial occlusion. Several growth factors are expressed in GCA lesions and may participate in vascular remodeling, including endothelin-1, PDGFs, transforming growth factor-beta 1 (TGF-beta 1), and neurotrophic factors [<a href="#rid56">56-60</a>]. Micro ribonucleic acids (RNAs) modulating myofibroblast differentiation, some of them regulated by PDGFs, have been recently identified in lesions [<a href="#rid61">61,62</a>]. Among growth factors expressed in lesions, endothelin-1 and PDGFs have been functionally explored [<a href="#rid56">56-59</a>]. PDGF receptor signaling blockade with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate results in reduced myointimal cell growth from cultured arteries [<a href="#rid56">56</a>]. A similar effect is observed with endothelin-1 receptor antagonists [<a href="#rid58">58,60</a>]. Increased circulating concentrations of endothelin-1 have been observed in patients with neuro-ophthalmic ischemic complications, suggesting a role in vascular occlusion [<a href="#rid56">56</a>]. Because expression of endothelin-1, PDGFs, and TGF-beta-1 is not substantially reduced by short-term exposure to glucocorticoids, specific targeting of vascular remodeling factors may be necessary to prevent or reduce vascular stenoses and occlusion [<a href="#rid3">3,4,23,56</a>].</p><p class="headingAnchor" id="H3304102044"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117108.html" rel="external">"Society guideline links: Giant cell arteritis and polymyalgia rheumatica"</a>.)</p><p class="headingAnchor" id="H489530924"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of giant cell arteritis (GCA) is incompletely understood. GCA is an immune-mediated disease occurring in susceptible individuals, but the nature of the triggering agent(s) is unknown. (See <a class="local">'Introduction'</a> above and <a class="local">'Predisposing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After initial events involving both innate and adaptive immune responses, amplification cascades in multiple inflammatory pathways lead to the progression of inflammatory infiltrates through the artery wall. Vascular components actively participate in this process. (See <a class="local">'Initial events'</a> above and <a class="local">'T lymphocyte functional differentiation'</a> above and <a class="local">'Amplification cascades'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation results in injury with vascular smooth muscle cell (VSMC) loss and elastic fiber breakdown, weakening the arterial muscular layer. (See <a class="local">'Vascular injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vascular response to inflammation leads to vascular remodeling, with resultant intimal hyperplasia and vessel occlusion. (See <a class="local">'Vascular remodeling and occlusion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effects of targeted therapies provide proof of concept regarding the relative contribution of different pathways sustaining and promoting vascular inflammation and remodeling in GCA. (See <a class="local">'Amplification cascades'</a> above.)</p><p></p><p class="headingAnchor" id="H3683992326"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gene G Hunder, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 2017; 13:578.</a></li><li><a class="nounderline abstract_t">Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989; 32:884.</a></li><li><a class="nounderline abstract_t">Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997; 99:2842.</a></li><li><a class="nounderline abstract_t">Corbera-Bellalta M, García-Martínez A, Lozano E, et al. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis 2014; 73:616.</a></li><li><a class="nounderline abstract_t">Terrades-Garcia N, Cid MC. Pathogenesis of giant-cell arteritis: How targeted therapies are influencing our understanding of the mechanisms involved. Rheumatology (Oxford) 2018; 57:ii51.</a></li><li><a class="nounderline abstract_t">Carmona FD, Mackie SL, Martín JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 2015; 96:565.</a></li><li><a class="nounderline abstract_t">Carmona FD, Vaglio A, Mackie SL, et al. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 2017; 100:64.</a></li><li><a class="nounderline abstract_t">Enjuanes A, Benavente Y, Hernández-Rodríguez J, et al. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology (Oxford) 2012; 51:841.</a></li><li><a class="nounderline abstract_t">Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51:264.</a></li><li><a class="nounderline abstract_t">Bhatt AS, Manzo VE, Pedamallu CS, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol 2014; 66:1939.</a></li><li><a class="nounderline abstract_t">Procop GW, Eng C, Clifford A, et al. Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association. Pathog Immun 2017; 2:228.</a></li><li><a class="nounderline abstract_t">Sammel AM, Smith S, Nguyen K, et al. Assessment for varicella zoster virus in patients newly suspected of having giant cell arteritis. Rheumatology (Oxford) 2020; 59:1992.</a></li><li><a class="nounderline abstract_t">Getz TM, Hoffman GS, Padmanabhan R, et al. Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms. Pathog Immun 2019; 4:105.</a></li><li><a class="nounderline abstract_t">Verdijk RM, Ouwendijk WJD, Kuijpers RWAM, Verjans GMGM. No Evidence of Varicella-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuropathy Patients With and Without Giant Cell Arteritis. J Infect Dis 2021; 223:109.</a></li><li><a class="nounderline abstract_t">Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199:173.</a></li><li><a class="nounderline abstract_t">Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2022; 81:524.</a></li><li><a class="nounderline abstract_t">Weyand CM, Schönberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994; 179:951.</a></li><li><a class="nounderline abstract_t">Coit P, De Lott LB, Nan B, et al. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis 2016; 75:1196.</a></li><li><a class="nounderline abstract_t">Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 2017; 114:E970.</a></li><li><a class="nounderline abstract_t">Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014; 66:768.</a></li><li><a class="nounderline abstract_t">Micaily I, Chernoff M. An unknown reaction to pembrolizumab: giant cell arteritis. Ann Oncol 2017; 28:2621.</a></li><li><a class="nounderline abstract_t">Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 2017; 69:837.</a></li><li><a class="nounderline abstract_t">Visvanathan S, Rahman MU, Hoffman GS, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology (Oxford) 2011; 50:2061.</a></li><li><a class="nounderline abstract_t">Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121:484.</a></li><li><a class="nounderline abstract_t">Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2013; 72:1481.</a></li><li><a class="nounderline abstract_t">Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121:906.</a></li><li><a class="nounderline abstract_t">Terrier B, Geri G, Chaara W, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012; 64:2001.</a></li><li><a class="nounderline abstract_t">Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43:294.</a></li><li><a class="nounderline abstract_t">Krupa WM, Dewan M, Jeon MS, et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002; 161:1815.</a></li><li><a class="nounderline abstract_t">Espígol-Frigolé G, Planas-Rigol E, Lozano E, et al. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. Front Immunol 2018; 9:809.</a></li><li><a class="nounderline abstract_t">Espígol-Frigolé G, Planas-Rigol E, Ohnuki H, et al. Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Sci Signal 2016; 9:ra28.</a></li><li><a class="nounderline abstract_t">Ciccia F, Rizzo A, Guggino G, et al. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford) 2015; 54:1596.</a></li><li><a class="nounderline abstract_t">Zerbini A, Muratore F, Boiardi L, et al. Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology (Oxford) 2018; 57:64.</a></li><li><a class="nounderline abstract_t">Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 2017; 76:898.</a></li><li><a class="nounderline abstract_t">Samson M, Greigert H, Ciudad M, et al. Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. Clin Transl Immunology 2021; 10:e1332.</a></li><li><a class="nounderline abstract_t">Ciccia F, Rizzo A, Maugeri R, et al. Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis 2017; 76:235.</a></li><li><a class="nounderline abstract_t">van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 2014; 66:1927.</a></li><li><a class="nounderline abstract_t">Graver JC, Boots AMH, Haacke EA, et al. Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. Front Immunol 2019; 10:83.</a></li><li><a class="nounderline abstract_t">Corbera-Bellalta M, Planas-Rigol E, Lozano E, et al. Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2016; 75:1177.</a></li><li><a class="nounderline abstract_t">van Sleen Y, Wang Q, van der Geest KSM, et al. Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis. Sci Rep 2017; 7:6553.</a></li><li><a class="nounderline abstract_t">Ciccia F, Alessandro R, Rizzo A, et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis 2013; 72:258.</a></li><li><a class="nounderline abstract_t">Cid MC, Cebrián M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000; 43:184.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621.</a></li><li><a class="nounderline abstract_t">Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73:2074.</a></li><li><a class="nounderline abstract_t">Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377:317.</a></li><li><a class="nounderline abstract_t">Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022; 81:653.</a></li><li><a class="nounderline abstract_t">Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation 2018; 137:1934.</a></li><li><a class="nounderline abstract_t">Koster MJ, Crowson CS, Giblon RE, et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis 2022; 81:861.</a></li><li><a class="nounderline abstract_t">Cid MC, Hernández-Rodríguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106:1664.</a></li><li><a class="nounderline abstract_t">Wen Z, Shen Y, Berry G, et al. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107:2428.</a></li><li><a class="nounderline abstract_t">Samson M, Ly KH, Tournier B, et al. Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. J Autoimmun 2016; 72:73.</a></li><li><a class="nounderline abstract_t">Rittner HL, Kaiser M, Brack A, et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999; 84:1050.</a></li><li><a class="nounderline abstract_t">Segarra M, García-Martínez A, Sánchez M, et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007; 66:1429.</a></li><li><a class="nounderline abstract_t">García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59:422.</a></li><li><a class="nounderline abstract_t">Lozano E, Segarra M, García-Martínez A, et al. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 2008; 67:1581.</a></li><li><a class="nounderline abstract_t">Lozano E, Segarra M, Corbera-Bellalta M, et al. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis 2010; 69:434.</a></li><li><a class="nounderline abstract_t">Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, et al. Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis 2017; 76:1624.</a></li><li><a class="nounderline abstract_t">Ly KH, Régent A, Molina E, et al. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling. Arthritis Res Ther 2014; 16:487.</a></li><li><a class="nounderline abstract_t">Régent A, Ly KH, Groh M, et al. Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. Autoimmun Rev 2017; 16:398.</a></li><li><a class="nounderline abstract_t">Croci S, Zerbini A, Boiardi L, et al. MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. Ann Rheum Dis 2016; 75:1527.</a></li><li><a class="nounderline abstract_t">Bolha L, Pižem J, Frank-Bertoncelj M, et al. Identification of microRNAs and their target gene networks implicated in arterial wall remodelling in giant cell arteritis. Rheumatology (Oxford) 2020; 59:3540.</a></li></ol></div><div id="topicVersionRevision">Topic 8234 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28905861" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2787641" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185506" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23625984" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982777" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pathogenesis of giant-cell arteritis: How targeted therapies are influencing our understanding of the mechanisms involved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25817017" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041642" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258388" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077270" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24644069" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28758156" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776576" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assessment for varicella zoster virus in patients newly suspected of having giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30993253" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32901261" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : No Evidence of Varicella-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuropathy Patients With and Without Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734523" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35045965" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Blocking GM-CSF receptorαwith mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113687" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038090" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28115719" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574239" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28633343" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An unknown reaction to pembrolizumab: giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133925" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873264" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067646" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22993227" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142449" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Th17 and Th1 T-cell responses in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147555" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679293" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414528" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29731755" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980441" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862016" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968695" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased expression of interleukin-22 in patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27927642" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34532040" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27098405" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ectopic expression of CXCL13, BAFF, APRIL and LT-βis associated with artery tertiary lymphoid organs in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623536" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30761147" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26698852" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Blocking interferonγreduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747747" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22872024" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643715" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470830" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897775" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745999" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trial of Tocilizumab in Giant-Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264321" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254929" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35190385" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270860" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724574" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742994" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27236507" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Involvement and prognosis value of CD8(+) T cells in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325242" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tissue-destructive macrophages in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502363" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gelatinase expression and proteolytic activity in giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18311764" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584806" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289383" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28606962" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418464" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232168" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342092" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32594153" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identification of microRNAs and their target gene networks implicated in arterial wall remodelling in giant cell arteritis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
